Movement Alert｜3SBio Rises 8% in Regular Trading, ASCO Annual Meeting SSGJ-707 Clinical Data Continues to Drive Momentum

Market Focus06-01

On June 1, 3SBio rose 8% in regular trading, trading at HK$19.79/share, with trading volume of HK$137 million. The stock continues to be propelled by clinical data unveiled at the ASCO Annual Meeting.

On the news front, 3SBio's core pipeline asset, PD-1/VEGF bispecific antibody SSGJ-707, had two clinical studies selected for presentation at the ASCO Annual Meeting, with one earning a Rapid Oral Communication slot. According to published abstracts, the Phase II study of SSGJ-707 monotherapy in advanced NSCLC demonstrated a confirmed ORR of 67.6% with a median PFS of 12.4 months. In first-line treatment of endometrial cancer combined with chemotherapy, confirmed ORR reached 85.7% and 80.0%, respectively—data widely regarded as impressive in the field.

Within the Biotechnology sector, several peers also posted gains, with AKESO up 6.94%, SKB BIO up 5.06%, and REMEGEN up 2.54%, reflecting broad sector strength that further bolstered market sentiment around 3SBio.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1137736241?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137736241","market":"hk","top_or_hot":-1,"title":"Movement Alert｜3SBio Rises 8% in Regular Trading, ASCO Annual Meeting SSGJ-707 Clinical Data Continues to Drive Momentum","media":"Market Focus","content":"<p><p>On June 1, 3SBio rose 8% in regular trading, trading at HK$19.79/share, with trading volume of HK$137 million. The stock continues to be propelled by clinical data unveiled at the ASCO Annual Meeting.</p><p>On the news front, 3SBio's core pipeline asset, PD-1/VEGF bispecific antibody SSGJ-707, had two clinical studies selected for presentation at the ASCO Annual Meeting, with one earning a Rapid Oral Communication slot. According to published abstracts, the Phase II study of SSGJ-707 monotherapy in advanced NSCLC demonstrated a confirmed ORR of 67.6% with a median PFS of 12.4 months. In first-line treatment of endometrial cancer combined with chemotherapy, confirmed ORR reached 85.7% and 80.0%, respectively—data widely regarded as impressive in the field.</p><p>Within the Biotechnology sector, several peers also posted gains, with AKESO up 6.94%, SKB BIO up 5.06%, and REMEGEN up 2.54%, reflecting broad sector strength that further bolstered market sentiment around 3SBio.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜3SBio Rises 8% in Regular Trading, ASCO Annual Meeting SSGJ-707 Clinical Data Continues to Drive Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜3SBio Rises 8% in Regular Trading, ASCO Annual Meeting SSGJ-707 Clinical Data Continues to Drive Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-01 09:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 1, 3SBio rose 8% in regular trading, trading at HK$19.79/share, with trading volume of HK$137 million. The stock continues to be propelled by clinical data unveiled at the ASCO Annual Meeting.</p><p>On the news front, 3SBio's core pipeline asset, PD-1/VEGF bispecific antibody SSGJ-707, had two clinical studies selected for presentation at the ASCO Annual Meeting, with one earning a Rapid Oral Communication slot. According to published abstracts, the Phase II study of SSGJ-707 monotherapy in advanced NSCLC demonstrated a confirmed ORR of 67.6% with a median PFS of 12.4 months. In first-line treatment of endometrial cancer combined with chemotherapy, confirmed ORR reached 85.7% and 80.0%, respectively—data widely regarded as impressive in the field.</p><p>Within the Biotechnology sector, several peers also posted gains, with AKESO up 6.94%, SKB BIO up 5.06%, and REMEGEN up 2.54%, reflecting broad sector strength that further bolstered market sentiment around 3SBio.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"","article_id":"1137736241","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137736241","pubTimestamp":1780277492,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 1, 3SBio rose 8% in regular trading, trading at HK$19.79/share, with trading volume of HK$137 million. The stock continues to be propelled by clinical data unveiled at the ASCO Annual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"动向提示|三生制药常规交易涨8%，ASCO年会SSGJ-707临床数据继续推动动能","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"On June 1, 3SBio rose 8% in regular trading, trading at HK$19.79/share, with trading volume of HK$137 million. The stock continues to be propelled by clinical data unveiled at the ASCO Annual Meeting.On the news front, 3SBio's core pipeline asset, PD-1/VEGF bispecific antibody SSGJ-707, had two clinical studies selected for presentation at the ASCO Annual Meeting, with one earning a Rapid Oral Communication slot. According to published abstracts, the Phase II study of SSGJ-707 monotherapy in advanced NSCLC demonstrated a confirmed ORR of 67.6% with a median PFS of 12.4 months. In first-line treatment of endometrial cancer combined with chemotherapy, confirmed ORR reached 85.7% and 80.0%, respectively—data widely regarded as impressive in the field.Within the Biotechnology sector, several peers also posted gains, with AKESO up 6.94%, SKB BIO up 5.06%, and REMEGEN up 2.54%, reflecting broad sector strength that further bolstered market sentiment around 3SBio.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137736241","isCrawlerRequest":true}